Abstract: The specification describes an antibody capture process comprising (i) obtaining a biological sample comprising antibodies, (ii) contacting the biological sample with recombinant pIgR or a dIgA-binding variant, wherein the pIgR or variant binds dIgA and forms a pIgR-dIgA complex. The process may further comprise (iii) directly or indirectly assessing the level of the pIgR-dIgA complex or the level of a complex between pIgR-dIgA and an antigen of interest. There is also an antibody capture process for determining gut wall integrity in a test subject, wherein the level or ratio of SIgA to dIgA is compared to a corresponding level or ratio from a control subject. The specification provides kits embodying the process and recombinant pIgR when used for, or for use, in capturing or detecting dIgA and/or IgM.

Abstract: The invention relates to compounds of Formula (I): wherein R1, R2 and R3 are as defined in the description and claims, or pharmaceutically acceptable salts thereof, having ?v?6 integrin antagonist activity. The invention also relates to pharmaceutical compositions including a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and to the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof in therapy, including in the treatment of a disease or condition for which an ?v?6 integrin antagonist is indicated, in particular the treatment of idiopathic pulmonary fibrosis.

Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.

Abstract: A compound of formula (I) or a salt thereof wherein R1 represents a hydrogen atom, a methyl group or a ethyl group R2 represents a hydrogen atom or a fluorine atom R3 represents a hydrogen atom, a methyl group or an ethyl group.

Abstract: An immunoassay suitable for point of care to assess liver disease or function comprising contacting a blood sample from a subject with a specific binding agent that recognizes an epitope of ALT1, that is not recognized by rodent antibodies when the rodent antibodies are in the presence of human plasma, to form an antigen-binding agent complex and detecting the complex using a second or further binding agent linked to or comprising a detectable reporter; and detecting liver disease or liver function in the subject contingent upon the mass concentration of ALT1 in the sample. Kits or devices comprising lagomorph antibodies or binding agents comprising the antigen binding component thereof suitable for measuring the mass concentration of ALT1 in a blood sample from a subject to determine liver function.

Abstract: A compound of formula (I): being 4-(3-Fluoro-3-(2-(5, 6, 7, 8-tetrahydro-1, 8-naphthyridin-2-yl) ethyl) pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy) phenyl) butanoic acid, or a salt thereof.

Abstract: The assembly disclosed herein is to attach a mast used by an off-road vehicle to the off-road vehicle itself using a mount assembly and a base assembly. The mount assembly is formed for the most part from non-magnetic materials is attached to an off-road vehicle by a ferromagnetic bolt at its proximal end. The base assembly is inserted into the mount assembly's open distal end the base assembly having a magnet attached to its proximal end that attracts the ferromagnetic bolt in the mount assembly and an opening at its distal end to receive an adapter that is connected to a mast. The proximal end of the base assembly having a surface effect that is received by the ferromagnetic bolt to prevent base assembly from rotating within the mount assembly.

Abstract: A compound of formula (I): being 4-(3-Fluoro-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl) ethyl) pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy) phenyl) butanoic acid, or a salt thereof.

Abstract: Embodiments are directed towards push signaling to run jobs on available servers. Users may provide jobs or job instructions to a job control node. Job control node may determine one or more available job target nodes from among a plurality of managed nodes associated with the job control node. The job target nodes may be determined based on information included in the provided job instructions. If there are available job target nodes, the job control node may provide the job instructions to each available job target node. Further, the job control node may receive communications from one or more available job target nodes that indicates that the job target node is prepared and ready to execute the received job instructions. Next, the job control node may issue a job start command that triggers the prepared job target nodes to begin executing the provided job instructions.

Abstract: This disclosure describes a biotechnological method for producing rebaudioside M (Reb M), using recombinantly produced glucosyltransferases, which can be carried out in a single reaction vessel using two glucosyltransferases and a uridine diphosphate glucose (UDPG) regenerating system. The method can be used to produce the commercially desirable Reb M from rubusoside, stevioside, or rebaudioside A (Reb A), which are all naturally more abundant steviol glycosides but with commercially less desirable properties.

Abstract: Embodiments of the present disclosure are directed towards techniques and configurations for an apparatus configured to provide I/O classification information in a distributed cloud storage system, in accordance with some embodiments. In one embodiment, the apparatus may include a partition scanner, to scan an image of a virtual disk associated with the storage system, to determine one or more partitions associated with the virtual disk; a file system scanner coupled with the partition scanner, to identify file systems associated with the determined partitions, to access files stored in the identified file systems; and I/O classifier coupled with the file system scanner, to generate I/O classification information associated with the accessed files. The I/O classification information provides characteristics of input-output operations performed on the virtual disk. Other embodiments may be described and/or claimed.

Abstract: The invention relates to compounds of Formula (I): wherein R1, R2 and R3 are as defined in the description and claims, or pharmaceutically acceptable salts thereof, having ?v?6 integrin antagonist activity. The invention also relates to pharmaceutical compositions including a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and to the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof in therapy, including in the treatment of a disease or condition for which an ?v?6 integrin antagonist is indicated, in particular the treatment of idiopathic pulmonary fibrosis.

Abstract: The coupling kit disclosed herein to attached a mast used by off-road vehicles to the frame of the off-road vehicle provides three advantages not seen in prior art. The first advantage is that of the two components of a coupling kit one is an off-the-shelf product thus reducing the cost of manufacture. The second is that the coupling kit allows for damaged or broken masts to be quickly replaced without the use of tools by another mast or that masts may be easily transferred from one off-road vehicle to another. The third is that the coupling kit does not allow the mast to rotate about its longitudinal axis.

Abstract: A compound of formula (I) or a salt thereof: wherein R1 represents a five-membered aromatic heterocycle selected from a N- or a C-linked mono- or di-substituted pyrazole, an N- or a C-linked optionally mono- or di-substituted triazole or an N- or a C-linked optionally mono- or di-substituted imidazole, which five-membered aromatic heterocycle may be substituted by one or two of the groups selected from a hydrogen atom, a methyl group, an ethyl group, a fluorine atom, a hydroxymethyl group, a 2-hydroxypropan-2-yl group, a trifluoromethyl group, a difluoromethyl group or a fluoromethyl group, except that when R1 represents an N-linked mono- or di-substituted pyrazole, R1 does not represent 3,5-Dimethyl-1H-pyrazol-1-yl, 5-Methyl-1H-pyrazol-1-yl, 5-Ethyl-3-methyl-1H-pyrazol-1-yl, 3,5-Diethyl-1H-pyrazol-1-yl, 4-Fluoro-3,5-dimethyl-1H-pyrazol-1-yl, 3-Methyl-1H-pyrazol-1-yl or 1H-pyrazol-1-yl.

Abstract: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.

Abstract: A compound of formula (I) or a salt thereof: wherein R1 represents a five-membered aromatic heterocycle selected from a N- or a C-linked mono- or di-substituted pyrazole, an N- or a C-linked optionally mono- or di-substituted triazole or an N- or a C-linked optionally mono- or di-substituted imidazole, which five-membered aromatic heterocycle may be substituted by one or two of the groups selected a methyl group, an ethyl group, a fluorine atom, a hydroxymethyl group, a 2-hydroxypropan-2-yl group, a trifluoromethyl group, a difluoromethyl group or a fluoromethyl group, except that when R1 represents an N-linked mono- or di-substituted pyrazole, R1 does not represent 3,5-Dimethyl-1H-pyrazol-1-yl, 5-Methyl-1H-pyrazol-1-yl, 5-Ethyl-3-methyl-1H-pyrazol-1-yl, 3,5-Diethyl-1H-pyrazol-1-yl, 4-Fluoro-3,5-dimethyl-1H-pyrazol-1-yl, 3-Methyl-1H-pyrazol-1-yl or 1H-pyrazol-1-yl.

Abstract: A compound of formula (I) or a salt thereof wherein R1 represents a hydrogen atom, a methyl group or a ethyl group R2 represents a hydrogen atom or a fluorine atom R3 represents a hydrogen atom, a methyl group or an ethyl group.

Abstract: A compound of formula (I): being 4-(3-Fluoro-3-(2-(5, 6, 7, 8-tetrahydro-1, 8-naphthyridin-2-yl) ethyl) pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy) phenyl) butanoic acid, or a salt thereof.

Abstract: A compound of formula (I) or a salt thereof wherein R1 represents a hydrogen atom, a methyl group or a ethyl group R2 represents a hydrogen atom or a fluorine atom R3 represents a hydrogen atom, a methyl group or an ethyl group.